Picard Medical financials
$4.45−3.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $4.9M |
| Gross profit | -$204.0K |
| Gross margin | −4.1% |
| Operating income | -$13.3M |
| Net income | -$27.0M |
| Net margin | −546.6% |
| Diluted EPS | $-37.50 |
| EBITDA | -$13.1M |
| Operating cash flow | -$15.7M |
| Free cash flow | -$15.7M |
| Diluted shares | 0.7M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $7.5M |
| Short-term investments | $0.00 |
| Total debt | $5.6M |
| Total assets | $22.5M |
| Total liabilities | $18.8M |
| Shareholders' equity | $3.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology